Biospring Partners Backs Serán Bioscience's Spray Dry Push

Serán Bioscience has secured a growth investment from Biospring Partners to strengthen its spray dry capabilities, accelerate commercial expansion and meet surging customer demand, the companies announced via Business Wire.

The deal positions Serán, a contract development and manufacturing organization specializing in spray-dried dispersions, to scale capacity at a moment when pharmaceutical developers are increasingly turning to the technology to solve bioavailability problems. Biospring Partners, a growth equity investor focused on the life sciences tools and services sector, is making the bet as demand for spray drying capacity outstrips supply across the CDMO market.

What does the investment fund?

According to the announcement, the capital will go toward three priorities:

• Strengthening and expanding spray dry capabilities
• Accelerating Serán's commercial expansion
• Scaling operations to meet surging customer demand

Spray drying has become a critical processing technology for formulated drug products, particularly for poorly soluble compounds that require amorphous dispersions to achieve therapeutic levels in patients. CDMOs with proven spray-drying expertise have attracted outsized investor attention as biopharma companies look for reliable manufacturing partners.

Who are the parties?

Serán Bioscience provides development and manufacturing services centered on spray drying and related formulation technologies. The company has built its reputation on serving customers who need spray-dried dispersions for oral and other routes of administration.

Biospring Partners is a growth investment firm targeting companies in the life sciences and healthcare technology sectors. Its investment in Serán signals conviction that demand for specialized manufacturing services will continue to outpace available capacity.

Why does this deal matter now?

The announcement frames the transaction as a direct response to customer demand that has grown faster than Serán's existing capabilities can absorb. Growth capital from an outside investor allows the CDMO to add capacity and commercial infrastructure without diverting resources from ongoing client programs.

For Biospring Partners, the deal adds a specialized manufacturing services asset to its portfolio at a point when pharma outsourcing continues to expand. Financial terms, including the investment amount and valuation, were not disclosed in the announcement.

The expansion sets up a straightforward test: whether Serán can convert added spray dry capacity into sustained commercial growth before competitors close the demand gap.